September 28, 2026

Rewriting the Rulebook for In Vivo CAR-T Formulation

Separating targeting from vector engineering could help reduce barriers to scalable in vivo CAR-T development while preserving existing manufacturing workflows. The article begins on page 45 of the September 2026 issue of European Pharmaceutical Review.

Media Inquiries

For inquiries, please contact mediarelations@vyriad.com